文献速递慢阻肺

未纳入大型临床试验的慢阻肺患者预后研究

Prognosis of Patients with Chronic Obstructive Pulmonary Disease Not Eligible for Major Clinical Trials.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01

在丹麦105,630名成人的当代人群队列中,仅44%的慢阻肺患者符合大型临床试验常见纳入标准;被排除者在 median 8.9 年随访中仍有显著升高的急性加重和全因死亡风险,提示当前试验证据覆盖不足。

要点

  • 一般人群中超过半数慢阻肺患者不符合大型临床试验纳入标准。
  • 被试验排除的慢阻肺患者急性加重风险仍显著高于无慢阻肺的症状吸烟者。
  • 被试验排除的慢阻肺患者全因死亡风险亦高于无慢阻肺的症状吸烟者。

核心结论

  • 一般人群中超过半数慢阻肺患者被大型临床试验排除,但这些患者仍存在临床显著的急性加重和早期死亡风险。
  • 与无慢阻肺的症状吸烟者相比,被试验排除和符合试验标准的慢阻肺患者急性加重及全因死亡风险均升高。

研究设计与样本

  • 基于丹麦当代人群的队列研究,纳入105,630名成人。
  • 慢阻肺定义为年龄≥40岁、慢性呼吸道症状、吸烟暴露史且FEV1/FVC<0.70。
  • 以无慢阻肺的症状吸烟者作为参照组,结局包括急性加重和全因死亡。

主要发现

  • 7,516人(7%)为有症状的慢阻肺患者,16,079人(15%)为无慢阻肺的症状吸烟者。
  • 应用FEV1<预计值80%、吸烟史≥10包年、无合并哮喘等常见纳入标准时,仅44%的慢阻肺患者符合大型临床试验条件。
  • 中位随访8.9年期间,有症状吸烟者中共观察到2,130次急性加重和3,973例死亡。
  • 与无慢阻肺的症状吸烟者相比,被试验排除和符合试验标准的慢阻肺患者急性加重多变量校正风险比分别为7.45(95%CI 5.41-10.3)和29.0(95%CI 21.1-39.8)。
  • 相应的全因死亡多变量校正风险比分别为1.21(95%CI 1.11-1.31)和1.67(95%CI 1.54-1.81)。

临床怎么用

  • 临床应认识到大型临床试验证据可能不覆盖多数真实世界慢阻肺患者。
  • 对不符合试验纳入标准的慢阻肺患者仍需重视急性加重和死亡风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Randomized controlled trials only include a subset of patients with chronic obstructive pulmonary disease (COPD) fulfilling strict inclusion criteria. Thus, most patients with COPD in a real-world setting do not have the necessary evidence to support treatment effectiveness. Objectives: To test the hypotheses that most individuals with COPD in the general population are not represented in major clinical trials despite clinically significant disease with exacerbations and early death. Methods: In 105,630 adults from a Danish contemporary population-based cohort, we defined COPD as age 40 or more years, chronic respiratory symptoms, history of smoking exposure, and airflow limitation with FEV1/FVC < 0.70. Outcomes included acute exacerbations and all-cause mortality. Symptomatic smokers without COPD were used as a reference group. Measurements and Main Results: Of all, 7,516 (7%) and 16,079 (15%) were symptomatic smokers with and without COPD. Only 44% of those with COPD were eligible for major clinical trials when applying FEV1 < 80% predicted, smoking history of 10 or more pack-years, and no comorbid asthma as common inclusion criteria. During the median 8.9 years of follow-up, we observed 2,130 acute exacerbations and 3,973 deaths in symptomatic smokers. Compared with symptomatic smokers without COPD, multivariable-adjusted hazard ratios for exacerbations were 7.45 (95% confidence interval, 5.41-10.3) and 29.0 (21.1-39.8) in those with COPD, respectively, excluded and eligible for clinical trials. Corresponding hazard ratios for all-cause mortality were 1.21 (1.11-1.31) and 1.67 (1.54-1.81), respectively. Conclusions: More than half of individuals with COPD in the general population are excluded from major clinical trials; however, these individuals have a clinically significant disease with exacerbations and early death compared with symptomatic smokers without COPD.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Çolak Y, Nordestgaard BG, Lange P, et al. Prognosis of Patients with Chronic Obstructive Pulmonary Disease Not Eligible for Major Clinical Trials. Am J Respir Crit Care Med. 2022. PMID: 35438616. doi:10.1164/rccm.202110-2441OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。